secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENANTA PHARMACEUTICALS INC (ENTA)
CIK:        0001177648
Form:       8-K
Filed at:   2023-04-27T23:59:59+00:00
Accession:  0001193125-23-122434
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enanta sells 54.5% of MAVYRET royalties to OMERS for $200M; non-dilutive funding
--------------------------------------------------------------------------------

- Sold 54.5% of future royalty payments on MAVYRET/MAVIRET worldwide sales to OMERS Life Sciences for $200M.
- OMERS receives royalty payments from July 2023 through June 2032, capped at 1.42x purchase price ($284M).
- Enanta retains 45.5% of royalties until cap is reached, then 100% reverts to Enanta.
- Proceeds to fund clinical development of pipeline therapies for viral infections; transaction is non-dilutive.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1177648/000119312523122434/0001193125-23-122434-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1177648/000119312523122434/d500394d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-122434

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer